You can buy or sell VIVUS and other stocks, options, ETFs, and crypto commission-free!
VIVUS, Inc. engages in the development and commercialization of novel therapeutic products. The firm's products are indicated for the treatment of obese and overweight patients, exocrine pancreatic insufficiency, and erectile dysfunction. Read More Its products include PANCREAZE, Qsymia, and STENDRA/SPEDRA. The company was founded by Virgil A. Place in April 16, 1991 and is headquartered in Campbell, CA.
52 Week High
52 Week Low
Why Vivus Is Trading Lower Today
Vivus (NASDAQ: VVUS) shares were trading lower on Wednesday, after the company priced its 7.22 million share common stock offering at $1.60 per share. Vivus is
BRIEF-Vivus Announces $11.55 Mln Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
April 1 (Reuters) - Vivus Inc: * VIVUS ANNOUNCES $11.55 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES * VIVUS INC - ENTERED INTO
— per share
Expected Apr 28, After Hours